In January 2022, the Milken Institute published a report, “Cell and Gene Therapies: Looking Ahead to 2022,”1 describing the growth of the CGT industry in 2021. In the U.S., 7 new therapies were approved for commercialization, a similar number were approved in Europe, and greater than 1,000 therapies were in development, with 75 expected to be approved in the U.S. by 2030.
